STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused…
February 10, 2025 Groundbreaking program that provides technology and training is reducing the impact of stroke, one of the leading…
MELBOURNE, Australia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers…
Leiden, the Netherlands, February 10, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in…
In conjunction with the royalty financing deal with HealthCare Royalty (HCRx) announced on January 30, 2025, GENFIT will request the…
RIYADH, Saudi Arabia, Feb. 09, 2025 (GLOBE NEWSWIRE) -- Saudi Arabia’s King Faisal Specialist Hospital & Research Centre (KFSHRC) –…
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen…
At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended…
February 08, 2025 14:30 ET | Source: 4D Molecular Therapeutics, Inc. 3E10 vg/eye achieved an 83% reduction in injection burden…
February 07, 2025 16:30 ET | Source: ORIC Pharmaceuticals SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 07, 2025 (GLOBE…